Implementing Subcutaneous Without Disruption

EP: 1.The Shifting to Subcutaneous Oncology: Recent FDA Approvals

EP: 2.Subcutaneous Value: Efficiency and Access

EP: 3.Workflow Wins: Scheduling and Pharmacy Impact

EP: 4.IV vs Subcutaneous: Clinical Considerations

EP: 5.Reimbursement Realities: Billing for Subcutaneous

Now Viewing

EP: 6.Implementing Subcutaneous Without Disruption

Successfully integrating SubQ therapies into oncology practice requires a comprehensive approach centered on education. It is essential that the entire care team—including physicians, nurses, pharmacists, and administrative staff—have a clear understanding of the differences between SubQ and intravenous (IV) treatments. This shared knowledge ensures consistent communication about efficacy, adverse effects, and the practical aspects of administration. Educating patients in straightforward language fosters trust and helps them feel confident in the treatment plan. Explaining how the SubQ formulation works, including the role of enzymes that facilitate drug absorption, can alleviate patient concerns about effectiveness and safety.

In addition to education, optimizing the clinical workflow is crucial. Practices need to strategically determine which patients and disease types are best suited for SubQ administration and plan accordingly to prevent disruption. This includes considerations around scheduling, chair availability, and balancing SubQ treatments alongside existing IV therapies. Open and transparent discussions about the potential cost differences of SubQ options should also be part of the patient conversation to avoid unexpected financial burdens. Clear operational protocols must be established so that nursing and pharmacy staff are comfortable with drug preparation, administration speed, and managing patient inquiries about the new approach.

Finally, continuous evaluation is vital to ensure that the integration of SubQ therapies enhances patient care without creating inefficiencies. Regularly reviewing patient outcomes, adherence rates, and workflow effectiveness allows for ongoing adjustments that support both clinical and operational success. By aligning education, workflow management, and financial considerations, oncology practices can effectively incorporate SubQ treatments into their clinical model, ultimately improving patient experience and maintaining high standards of care.